Therapeutic applications of thymosin peptides: a patent landscape 2018-present

References

• Goldstein AL, Slater FD, White A. Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proc Natl Acad Sci USA. 1966;56(3):1010–1017.
   PubMed Web of Science ®Google Scholar
• Hannappel E, Huff T. The thymosins. Vitamins & hormones. Elsevier; 2003p. 257–296. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0083672903010070
   Google Scholar
• Tl L, Al G. Thymosins: structure, function and therapeutic applications. Thymus. 1984; 6. Available from: https://pubmed.ncbi.nlm.nih.gov/6087503/
   Google Scholar
• Goldstein AL, Low TL, McAdoo M, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA. 1977;74(2):725–729. doi: 10.1073/pnas.74.2.725
   PubMed Web of Science ®Google Scholar
• Chen C, Li M, Yang H, et al. Roles of thymosins in cancers and other organ systems. World J Surg. 2005;29(3):264–270. doi: 10.1007/s00268-004-7817-2
   PubMed Web of Science ®Google Scholar
• Low TLK, Goldstein AL. Thymosin α1 and polypeptide β1. Methods in Enzymology. Academic Press; 1985 15. p. 233–248. Available from: https://www.sciencedirect.com/science/article/pii/S0076687985160179
   Google Scholar
• Camerini R, Garaci E. Historical review of thymosin α 1 in infectious diseases. Expert Opin Biol Ther. 2015;15(sup1):117–127. doi: 10.1517/14712598.2015.1033393
   PubMed Web of Science ®Google Scholar
• Li J, Liu CH, Wang FS. Thymosin alpha 1: biological activities, applications and genetic engineering production. Peptides. 2010;31(11):2151–2158. doi: 10.1016/j.peptides.2010.07.026
   PubMed Web of Science ®Google Scholar
• Ahmed A, Wong DM, Thurman GB, et al. T-lymphocyte maturation: cell surface markers and immune function induced by T-lymphocyte cell-free products and thymosin polypeptides. Ann NY Acad Sci. 1979;332(1):81–94. doi: 10.1111/j.1749-6632.1979.tb47100.x
   PubMedGoogle Scholar
• Peng Y, Chen Z, Yu W, et al. Effects of thymic polypeptides on the thymopoiesis of mouse embryonic stem cells. Cell Biol Int. 2008;32(10):1265–1271. doi: 10.1016/j.cellbi.2008.07.011
   PubMed Web of Science ®Google Scholar
• Yao W, Zhu Q, Yuan Y, et al. Thymosin alpha 1 improves severe acute pancreatitis in rats via regulation of peripheral T cell number and cytokine serum level. J Gastroenterol Hepatol. 2007;22(11):1866–1871. doi: 10.1111/j.1440-1746.2006.04699.x
   PubMed Web of Science ®Google Scholar
• Rustgi VK. Thymalfasin for the treatment of chronic hepatitis C infection. Expert Rev Anti Infect Ther. 2005;3(6):885–892. doi: 10.1586/14787210.3.6.885
   PubMedGoogle Scholar
• Giuliani C, Napolitano G, Mastino A, et al. Thymosin-α1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur J Immunol. 2000;30(3):778–786. doi: 10.1002/1521-4141(200003)30:3<778:AID-IMMU778>3.0.CO;2-I
   PubMed Web of Science ®Google Scholar
• Garaci E, Favalli C, Pica F, et al. Thymosin alpha 1: from bench to bedside. Ann NY Acad Sci. 2007;1112(1):225–234. doi: 10.1196/annals.1415.044
   PubMedGoogle Scholar
• Armutcu F, Coskun O, Gürel A, et al. Thymosin alpha 1 attenuates lipid peroxidation and improves fructose-induced steatohepatitis in rats. Clin Biochem. 2005;38(6):540–547. doi: 10.1016/j.clinbiochem.2005.01.013
   PubMed Web of Science ®Google Scholar
• Schulof RS, Lloyd MJ, Cleary PA, et al. A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer. J Biol Response Mod. 1985;4(2):147–158.
   PubMedGoogle Scholar
• Dominari A, Hathaway III D, Pandav K, et al. Thymosin alpha 1: a comprehensive review of the literature. World J Virol. 2020;9(5):67–78. doi: 10.5501/wjv.v9.i5.67
   PubMedGoogle Scholar
• An T-T, Liu X-Y, Fang J, et al. Primary assessment of treatment effect of thymosin alpha1 on chemotherapy-induced neurotoxicity. Ai Zheng. 2004;23(11 Suppl):1428–1430.
   PubMedGoogle Scholar
• Camerini R, Mackiewicz A, Testori A, et al. A large first-line, randomized, dose-finding, phase II study on thymosin-alpha 1 (T-alpha 1) plus dacarbazine (DTIC) with or without interferon-alpha (IFN-alpha) compared to DTIC plus IFN-alpha in stage IV melanoma tumor response and survival results. JCO. 2007;25(18_suppl):8535–8535. doi: 10.1200/jco.2007.25.18_suppl.8535
   Web of Science ®Google Scholar
• Iino S, Toyota J, Kumada H, et al. The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial. J Viral Hepat. 2005;12(3):300–306. doi: 10.1111/j.1365-2893.2005.00633.x
   PubMed Web of Science ®Google Scholar
• Garaci E, Rocchi G, Perroni L, et al. Combination treatment with zidovudine, thymosin α1 and interferon-α in human immunodeficiency virus infection and interferon-α in human immunodeficiency virus infection. Int J Clin Lab Res. 1994;24(1):23–28. doi: 10.1007/BF02592405
   PubMedGoogle Scholar
• CHADWICK D, PIDO-LOPEZ J, PIRES A, et al. A pilot study of the safety and efficacy of thymosin α1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy. Clin Exp Immunol. 2003;134(3):477–481. doi: 10.1111/j.1365-2249.2003.02331.x
   PubMed Web of Science ®Google Scholar
• Sosne G, Christopherson PL, Barrett RP, et al. Thymosin-β4 modulates corneal matrix metalloproteinase levels and polymorphonuclear cell infiltration after alkali injury. Invest Ophthalmol Vis Sci. 2005;46(7):2388. doi: 10.1167/iovs.04-1368
   PubMed Web of Science ®Google Scholar
• Malinda KM, Goldstein AL, Kueinman HK. Thymosin β 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 1997;11(6):474–481. doi: 10.1096/fasebj.11.6.9194528
   PubMed Web of Science ®Google Scholar
• Krenning G, Zeisberg EM, Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol. 2010;225(3):631–637. doi: 10.1002/jcp.22322
   PubMed Web of Science ®Google Scholar
• Xing Y, Ye Y, Zuo H, et al. Progress on the function and application of thymosin β4. Front Endocrinol. 2021;12:767785. doi: 10.3389/fendo.2021.767785
   PubMed Web of Science ®Google Scholar
• Golla R, Philp N, Safer D, et al. Co-ordinate regulation of the cytoskeleton in 3T3 cells overexpressing thymosin-β4. Cell Motil Cytoskeleton. 1997;38(2):187–200. doi: 10.1002/(SICI)1097-0169(1997)38:2<187:AID-CM7>3.0.CO;2-4
   PubMed Web of Science ®Google Scholar
• Gerosa C, Fanni D, Nemolato S, et al. Thymosin beta-10 expression in developing human kidney. J Matern-Fetal Neonatal Med. 2010;23(sup3):125–128. doi: 10.3109/14767058.2010.510645
   PubMed Web of Science ®Google Scholar
• Hall AK. Thymosin beta-10 accelerates apoptosis. Cell Mol Biol Res. 1995;41(3):167–180.
   PubMedGoogle Scholar
• Sribenja S, Li M, Wongkham S, et al. Advances in thymosin β10 research: differential expression, molecular mechanisms, and clinical implications in cancer and other conditions. Cancer Invest. 2009;27(10):1016–1022. doi: 10.3109/07357900902849640
   PubMed Web of Science ®Google Scholar
• Koutrafouri V, Leondiadis L, Ferderigos N, et al. Synthesis and angiogenetic activity in the chick chorioallantoic membrane model of thymosin beta-15. Peptides. 2003;24(1):107–115. doi: 10.1016/S0196-9781(02)00282-6
   PubMed Web of Science ®Google Scholar
• Xu X, He K, Hoffman RD, et al. Thymosin beta 15 alters the spatial development of thymic epithelial cells. Cells. 2022;11(22):3679. doi: 10.3390/cells11223679
   PubMed Web of Science ®Google Scholar
• Efron N. 18 - corneal staining. In: Efron N, editor. Contact lens complications. Fourth. Philadelphia: Elsevier; 2019. p. 197–209. Available from: https://www.sciencedirect.com/science/article/pii/B9780702076114000182
   Google Scholar
• Chun YS, Yoon WB, Kim KG, et al. Objective assessment of corneal staining using digital image analysis. Invest Ophthalmol Visual Sci. 2014;55(12):7896–7903. doi: 10.1167/iovs.14-15618
   PubMed Web of Science ®Google Scholar
• Sosne G. Thymosin beta 4 and the eye: the journey from bench to bedside. Expert Opin Biol Ther. 2018;18(sup1):99–104. doi: 10.1080/14712598.2018.1486818
   PubMed Web of Science ®Google Scholar
• Sosne G, Chan CC, Thai K, et al. Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo. Exp Eye Res. 2001;72(5):605–608. doi: 10.1006/exer.2000.0985
   PubMed Web of Science ®Google Scholar
• Sosne G, Szliter EA, Barrett R, et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002;74(2):293–299. doi: 10.1006/exer.2001.1125
   PubMed Web of Science ®Google Scholar
• Treebnt Co Ltd G, Kang SW, Kim K, et al. Corneal damage prevention/treatment composition comprising thymosin beta 4 and citric acid as active ingredients. EP3338792. 2018.
   Google Scholar
• MEYERS RL, PETTIT TH. Chemotaxis of polymorphonuclear leukocytes in corneal inflammation: tissue injury in herpes simplex virus infection. Invest Ophthalmol Visual Sci. 1974;13:187–197.
   Google Scholar
• G. Treebnt Co Ltd. Lee SY, Kang SW. Method for preparing ophthalmic preparation containing thymosin beta-4. EP3342398. 2018
   Google Scholar
• Clayton JA, Longo DL. Dry Eye. N Engl J Med. 2018;378(23):2212–2223. doi: 10.1056/NEJMra1407936
   PubMed Web of Science ®Google Scholar
• Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491–496. doi: 10.1097/ICO.0000000000000379
   PubMed Web of Science ®Google Scholar
• Regentree L, Yang WS, Kang SW, et al. Methods of treating̥ dry eye syndrome. US2021213103 (2021).
   Google Scholar
• Huons Co. Ltd, Kim YM, Kim WP, et al. Pharmaceutical composition containing gly-thymosin beta-4 (gly-Tb4) for treatment of dry eye. US2022257721 (2022).
   Google Scholar
• Yoon K-C, Ahn K-Y, Choi W, et al. Tear production and ocular surface changes in experimental dry eye after elimination of desiccating stress. Invest Ophthalmol Vis Sci. 2011;52(10):7267–7273. doi: 10.1167/iovs.11-7231
   PubMed Web of Science ®Google Scholar
• Pajoohesh-Ganji A, Pal-Ghosh S, Tadvalkar G, et al. Corneal goblet cells and their niche: implications for corneal stem cell deficiency. Stem Cells. 2012;30(9):2032–2043. doi: 10.1002/stem.1176
   PubMed Web of Science ®Google Scholar
• G. Treebnt Co Ltd, Kang S, Kim K, et al. Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin beta 4 or derivative thereof as active ingredient. EP3715451 (2020).
   Google Scholar
• Chumburidze Georgy G, Chumburidze GG. Stabilized Composition. US2021113478 (2021).
   Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–2128. doi: 10.1016/S0140-6736(12)61728-0
   PubMed Web of Science ®Google Scholar
• Melanoma Treatment (PDQ®. NCI. 2023. Available from: https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq
   Google Scholar
• Sarna M, Krzykawska-Serda M, Jakubowska M, et al. Melanin presence inhibits melanoma cell spread in mice in a unique mechanical fashion. Sci Rep. 2019;9(1):9280. doi: 10.1038/s41598-019-45643-9
   PubMedGoogle Scholar
• Sun W, Schuchter LM. Metastatic melanoma. Curr Treat Options Oncol. 2001;2(3):193–202. doi: 10.1007/s11864-001-0033-5
   PubMedGoogle Scholar
• Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, et al. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev. 2018;2018(11): CD011123. doi: 10.1002/14651858.CD011123.pub2
   Google Scholar
• Treatment of cancer with immune stimulator alpha thymosin peptide. EP3943101. 2022.
   Google Scholar
• Miller KD, Ostrom QT, Kruchko C, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71(5):381–406. doi: 10.3322/caac.21693
   PubMed Web of Science ®Google Scholar
• Merrell RT. Brain tumors. Disease-A-Month. 2012;58(12):678–689. doi: 10.1016/j.disamonth.2012.08.009
   PubMed Web of Science ®Google Scholar
• Tan AC, Ashley DM, López GY, et al. Management of glioblastoma: state of the art and future directions. Ca A Cancer J Clinicians. 2020;70(4):299–312. doi: 10.3322/caac.21613
   PubMed Web of Science ®Google Scholar
• Roussel MF, Hatten ME. Cerebellum. Current topics in developmental biology. Elsevier; 2011. p. 235–282. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780123809162000085
   Google Scholar
• Waye S, Naeem A, Choudhry MU, et al. The p53 tumor suppressor protein protects against chemotherapeutic stress and apoptosis in human medulloblastoma cells. Aging. 2015;7(10):854–867. doi: 10.18632/aging.100831
   PubMedGoogle Scholar
• Naeem A, Harish V, Coste S, et al. Regulation of chemosensitivity in human medulloblastoma cells by p53 and the PI3 kinase signaling pathway. Mol Cancer Res. 2022;20(1):114–126. doi: 10.1158/1541-7786.MCR-21-0277
   PubMed Web of Science ®Google Scholar
• Univ Georgetown, Albanese C, Naeem A Enhancing chemotherapy in medulloblastoma and glioblastoma with high basal p53 levels. US2021244797 (2021).
   Google Scholar
• Funes SC, Manrique de Lara A, Altamirano-Lagos MJ, et al. Immune checkpoints and the regulation of tolerogenicity in dendritic cells: implications for autoimmunity and immunotherapy. Autoimmun Rev. 2019;18(4):359–368. doi: 10.1016/j.autrev.2019.02.006
   PubMed Web of Science ®Google Scholar
• Dutta S, Ganguly A, Chatterjee K, et al. Targets of immune escape mechanisms in cancer: basis for development and evolution of cancer immune checkpoint inhibitors. Biology. 2023;12(2):218. doi: 10.3390/biology12020218
   PubMedGoogle Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Wilky BA. Immune checkpoint inhibitors: the linchpins of modern immunotherapy. Immunol Rev. 2019;290(1):6–23. doi: 10.1111/imr.12766
   PubMed Web of Science ®Google Scholar
• Geukes Foppen MH, Rozeman EA, van Wilpe S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018;3(1):e000278. doi: 10.1136/esmoopen-2017-000278
   PubMed Web of Science ®Google Scholar
• Garaci E, Romani L, Renga G, et al. Method of treatment of immune checkpoint inhibitor-related immune adverse effects. US2021077585 (2021).
   Google Scholar
• Abolhassani H, Dabbaghzadeh A, Ahanchian H, et al.et al. Chapter 5 - diseases of immune dysregulation. In: Aghamohammadi A, Abolhassani H Rezaei N, editors. Inborn errors of immunity. Academic Press; 2021. p. 125–153. Available from: https://www.sciencedirect.com/science/article/pii/B9780128210284000051
   Google Scholar
• Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840–851. doi: 10.1056/NEJMra1208623
   PubMed Web of Science ®Google Scholar
• Cao C, Yu M, Chai Y. Pathological alteration and therapeutic implications of sepsis-induced immune cell apoptosis. Cell Death Dis. 2019;10(10):782. doi: 10.1038/s41419-019-2015-1
   PubMedGoogle Scholar
• Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the global burden of disease study. Lancet. 2020;395(10219):200–211. doi: 10.1016/S0140-6736(19)32989-7
   PubMed Web of Science ®Google Scholar
• Guan X, Wu J, Tuthill C, et al. Use of thymosin alpha for the treatment of sepsis. EP3741386. 2020.
   Google Scholar
• Study details | efficacy of thymosin alpha1 for severe sepsis |. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT00711620
   Google Scholar
• Heyworth PG, Cross AR, Curnutte JT. Chronic granulomatous disease. Curr Opin Immunol. 2003;15(5):578–584. doi: 10.1016/S0952-7915(03)00109-2
   PubMed Web of Science ®Google Scholar
• Rider NL, Jameson MB, Creech CB. Chronic granulomatous disease: epidemiology, pathophysiology, and genetic basis of disease. J Pediatric Infect Dis Soc. 2018;7(suppl_1):S2–S5. doi: 10.1093/jpids/piy008
   PubMed Web of Science ®Google Scholar
• Regenerx Biopharmaceuticals Inc, Romani L, Garaci E, et al. Compositions and methods for treatment of chronic granulomatous disease. US2022241378 (2022).
   Google Scholar
• Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942–955. doi: 10.1016/S0140-6736(10)61156-7
   PubMed Web of Science ®Google Scholar
• Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362(6415):59–62. doi: 10.1038/362059a0
   PubMed Web of Science ®Google Scholar
• Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in als. Annu Rev Neurosci. 2004;27(1):723–749. doi: 10.1146/annurev.neuro.27.070203.144244
   PubMedGoogle Scholar
• Xiao B, Xiao X, Li J, et al. Compositions and methods of using the same for treating disorders associated with thymosin beta 4. WO2023034966. 2023
   Google Scholar
• O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373(9678):1891–1904. doi: 10.1016/S0140-6736(09)60327-5
   PubMed Web of Science ®Google Scholar
• Lukacs GL, Verkman AS. CFTR: folding, misfolding and correcting the ΔF508 conformational defect. Trends Mol Med. 2012;18(2):81–91. doi: 10.1016/j.molmed.2011.10.003
   PubMed Web of Science ®Google Scholar
• Cantin AM, Hartl D, Konstan MW, et al. Inflammation in cystic fibrosis lung disease: pathogenesis and therapy. J Cyst Fibros. 2015;14(4):419–430. doi: 10.1016/j.jcf.2015.03.003
   PubMed Web of Science ®Google Scholar
• Belcher CN, Vij N. Protein processing and inflammatory signaling in cystic fibrosis: challenges and therapeutic strategies. Curr Mol Med. 2010;10(1):82–94. doi: 10.2174/156652410791065408
   PubMed Web of Science ®Google Scholar
• Sciclone Pharmaceuticals Int. Ltd, Romani L, Garaci E. Thymosin alpha 1 for use in treatment of cystic fibrosis. EP3865149 (2021).
   Google Scholar
• Choudhary A, Raines RT. An evaluation of peptide‐bond isosteres. Chembiochem. 2011;12(12):1801–1807. doi: 10.1002/cbic.201100272
   PubMed Web of Science ®Google Scholar
• Goodman M, Chorev M. On the concept of linear modified retro-peptide structures. Acc Chem Res. 1979;12(1):1–7. doi: 10.1021/ar50133a001
   Web of Science ®Google Scholar
• Copolovici DM, Langel K, Eriste E, et al. Cell-penetrating peptides: design, synthesis, and applications. ACS Nano. 2014;8(3):1972–1994. doi: 10.1021/nn4057269
   PubMed Web of Science ®Google Scholar
• Buss JE, Sefton BM. Direct identification of palmitic acid as the lipid attached to p21ras. Mol Cell Biol. 1986;6(1):116–122. doi: 10.1128/MCB.6.1.116
   PubMed Web of Science ®Google Scholar
• Lau YH, De Andrade P, Wu Y, et al. Peptide stapling techniques based on different macrocyclisation chemistries. Chem Soc Rev. 2015;44(1):91–102. doi: 10.1039/C4CS00246F
   PubMed Web of Science ®Google Scholar
• Carraro G, Naso A, Montomoli E, et al. Thymosin-alpha 1 (Zadaxin™) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria™) in hemodialyzed patients: a pilot study. Vaccine. 2012;30(6):1170–1180. doi: 10.1016/j.vaccine.2011.12.014
   PubMedGoogle Scholar